This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US health plans survive Biogen motion to dismiss with Robinson-Patman claims

By Clayton Vickers ( January 29, 2026, 20:34 GMT | Insight) -- US health benefit plans suing Biogen for allegedly bribing pharmacy benefit managers and unlawfully impairing competition from generic versions of Tecfidera overcame Biogen’s motion to dismiss by dropping claims for damages under the Sherman Act and asserting them under the Robinson-Patman Act and RICO.US health benefit plans suing Biogen for allegedly bribing pharmacy benefit managers and unlawfully impairing competition from generic versions of Tecfidera prevailed against Biogen’s motion to dismiss by dropping claims for damages under the Sherman Act and asserting them under the Robinson-Patman Act and RICO....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections